PASE whitepaper: more than a disease-based model

Submission to New Zealand Telehealth Leadership Group and Forum, 28 July 2022

Also in this category

Submissions

Migrating potential patient safety risk: Omeprazole 40mg and Flecainide 100mg capsules

Submission to Pharmaceutical Society of New Zealand

View resource
Submissions

Proposal to fund Ryzodeg

Submission to Pharmac,

View resource
Submissions

Putting Patients First: Modernising health workforce regulation

Submission to Ministry of Health

View resource